U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H6N2
Molecular Weight 94.1147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DALFAMPRIDINE

SMILES

c1c[nH]ccc1=N

InChI

InChIKey=NUKYPUAOHBNCPY-UHFFFAOYSA-N
InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)

HIDE SMILES / InChI

Molecular Formula C5H6N2
Molecular Weight 94.1147
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/cdi/dalfampridine.html | https://clinicaltrials.gov/ct2/show/NCT01356940 | https://www.ncbi.nlm.nih.gov/pubmed/22497693 | https://www.ncbi.nlm.nih.gov/pubmed/15084131

Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Originator

Sources: Zhurnal Russkago Fiziko-Khimicheskago Obshchestva (1915), 47, 835-8.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
195.0 µM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMPYRA

Approved Use

AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14)

Launch Date

1.2641184E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23.77 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DALFAMPRIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
246.48 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DALFAMPRIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.16 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DALFAMPRIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
97%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DALFAMPRIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.3
unhealthy, 52.1 ± 8.8
n = 269
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 52.1 ± 8.8
Sex: M+F
Population Size: 269
Sources: Page: p.3
Disc. AE: Seizure, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Seizure (1.1%)
Myocardial infarction (1.1%)
Sources: Page: p.3
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Disc. AE: Weakness, Consciousness decreased...
AEs leading to
discontinuation/dose reduction:
Weakness
Consciousness decreased
Memory loss
Hypophonia
Structural brain disorders NEC
Sources: Page: p.3
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Sex: F
Population Size: 1
Sources: Page: p.3
Disc. AE: Complex partial seizures, Confusion...
AEs leading to
discontinuation/dose reduction:
Complex partial seizures
Confusion
Sources: Page: p.3
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Disc. AE: Mental state abnormal...
AEs leading to
discontinuation/dose reduction:
Mental state abnormal
Sources: Page: p.3
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.2
unhealthy
n = 400
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 400
Sources: Page: p.2
Disc. AE: Headache, Balance disorder...
AEs leading to
discontinuation/dose reduction:
Headache (0.5%)
Balance disorder (0.5%)
Dizziness (0.5%)
Confusional state (0.5%)
Sources: Page: p.2
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
Disc. AE: Seizures...
AEs leading to
discontinuation/dose reduction:
Seizures
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Myocardial infarction 1.1%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.3
unhealthy, 52.1 ± 8.8
n = 269
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 52.1 ± 8.8
Sex: M+F
Population Size: 269
Sources: Page: p.3
Seizure 1.1%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.3
unhealthy, 52.1 ± 8.8
n = 269
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 52.1 ± 8.8
Sex: M+F
Population Size: 269
Sources: Page: p.3
Consciousness decreased Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Hypophonia Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Memory loss Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Structural brain disorders NEC Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Weakness Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Complex partial seizures Disc. AE
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Sex: F
Population Size: 1
Sources: Page: p.3
Confusion Disc. AE
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Sex: F
Population Size: 1
Sources: Page: p.3
Mental state abnormal Disc. AE
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources: Page: p.3
unhealthy
n = 1
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 1
Sources: Page: p.3
Balance disorder 0.5%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.2
unhealthy
n = 400
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 400
Sources: Page: p.2
Confusional state 0.5%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.2
unhealthy
n = 400
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 400
Sources: Page: p.2
Dizziness 0.5%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.2
unhealthy
n = 400
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 400
Sources: Page: p.2
Headache 0.5%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.2
unhealthy
n = 400
Health Status: unhealthy
Condition: Multiple sclerosis
Population Size: 400
Sources: Page: p.2
Seizures Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Multiple sclerosis
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [IC50 195 uM]
weak [IC50 270 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
minor
minor
minor
minor
minor
minor
minor
minor
no
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The expression and regulation of depolarization-activated K+ channels in the insulin-secreting cell line INS-1.
2001 Apr
Differential expression of KV and KCa channels in vascular smooth muscle cells during 1-day culture.
2001 Apr
General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals.
2001 Aug
Resolving the gating charge movement associated with late transitions in K channel activation.
2001 Aug
A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action.
2001 Aug
Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels.
2001 Aug
The relaxation induced by S-nitroso-glutathione and S-nitroso-N-acetylcysteine in rat aorta is not related to nitric oxide production.
2001 Aug
Chloride distribution in the CA1 region of newborn and adult hippocampus by light microscopic histochemistry.
2001 Feb
The effect of acidosis on the ECG of the rat heart.
2001 Jan
Diversity of K+ channels in circular smooth muscle of opossum lower esophageal sphincter.
2001 Jul
Pharmacological evidence for the activation of potassium channels as the mechanism involved in the hypotensive and vasorelaxant effect of dioclein in rat small resistance arteries.
2001 Jul
Imaging of 4-AP-induced, GABA(A)-dependent spontaneous synchronized activity mediated by the hippocampal interneuron network.
2001 Jul
KT3.2 and KT3.3, two novel human two-pore K(+) channels closely related to TASK-1.
2001 Jul
Long-term recordings of networks of immortalized GnRH neurons reveal episodic patterns of electrical activity.
2001 Jul
Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: variable role for smooth muscle hyperpolarization.
2001 Jul
Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells.
2001 Jul
Gap junctions synchronize the firing of inhibitory interneurons in guinea pig hippocampus.
2001 Jul 13
High glucose impairs voltage-gated K(+) channel current in rat small coronary arteries.
2001 Jul 20
Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity.
2001 Jul 20
A novel mechanical dissociation technique for studying acutely isolated maturing Drosophila central neurons.
2001 Jul 30
Role of K+ -channels in homotaurine-induced analgesia.
2001 Jun
Normal coordinate analysis of 4-aminopyridine. Effect of substituent on pyridine ring in metal complexes of 4-substituted pyridines.
2001 Jun
Focal cooling rapidly terminates experimental neocortical seizures.
2001 Jun
Pharmacological modulation of SK3 channels.
2001 Jun
Tonotopic map of potassium currents in chick auditory hair cells using an intact basilar papilla.
2001 Jun
Alterations in a redox oxygen sensing mechanism in chronic hypoxia.
2001 Jun
Superfusion of synaptosomes to study presynaptic mechanisms involved in neurotransmitter release from rat brain.
2001 Jun
Synchronized Ca2+ signals mediated by Ca2+ action potentials in the hippocampal neuron network in vitro.
2001 Jun
Potassium channels regulate tone in rat pulmonary veins.
2001 Jun
Mechanisms underlying presynaptic facilitatory effect of cyclothiazide at the calyx of Held of juvenile rats.
2001 Jun 1
Functional and molecular expression of a voltage-dependent K(+) channel (Kv1.1) in interstitial cells of Cajal.
2001 Jun 1
Skin surface electric potential induced by ion-flux through epidermal cell layers.
2001 Jun 1
Dopamine D4 receptor-deficient mice display cortical hyperexcitability.
2001 Jun 1
Membrane resonance and subthreshold membrane oscillations in mesencephalic V neurons: participants in burst generation.
2001 Jun 1
Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines.
2001 Jun 15
"Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium.
2001 Jun 22
Developmental characteristics of epileptiform activity in immature rat neocortex: a comparison of four in vitro seizure models.
2001 Jun 29
Potassium channel blocker TEA prevents CA1 hippocampal injury following transient forebrain ischemia in adult rats.
2001 Jun 8
The effects of different 4-aminopyridine and morphine combinations on the intensity of morphine abstinence.
2001 Mar
Modulation of voltage-dependent K+ channel current in vascular smooth muscle cells from rat mesenteric arteries.
2001 Mar 15
Capsaicin-induced relaxation in rabbit coronary artery.
2001 May
Time-dependent distribution and neuronal localization of c-fos protein in the rat hippocampus following 4-aminopyridine seizures.
2001 May
A redox-based mechanism for the contractile and relaxing effects of NO in the guinea-pig gall bladder.
2001 May 1
Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I(K,slow) and resistance to drug-induced qt prolongation.
2001 May 11
Stretch-dependent potassium channels in murine colonic smooth muscle cells.
2001 May 15
Oxygen dilation in fetal pulmonary arterioles: role of K(+) channels.
2001 May 15
Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels.
2001 May 15
minK-related peptide 1 associates with Kv4.2 and modulates its gating function: potential role as beta subunit of cardiac transient outward channel?
2001 May 25
Ion channels associated with the ectopic discharges generated after segmental spinal nerve injury in the rat.
2001 May 4
BTS 72664-- a novel CNS drug with potential anticonvulsant, neuroprotective, and antimigraine properties.
2001 Summer
Patents

Sample Use Guides

The maximum recommended dose of AMPYRA is one 10 mg tablet twice daily, taken with or without food, and should not be exceeded.
Route of Administration: Oral
At DIV25, the differentiating cells were re-seeded to Matrigel coated 12-mm glass coverslips in densities of 400,000 cells per well. Media was replaced completely the next day by fresh maturation media. Media containing either 100 mM 4-Aminopyridine diluted in DMSO or the equivalent amount DMSO only was given to the cells 72 hours before the start of week 7 (DIV42) and lasted until the cells were analyzed during week 7. Half the media was replaced every third day. Final electrophysiological recordings of the treated vs. non-treated cells rigorously were taken in pairs of one treated and one nontreated coverslip within a time frame of 48 hours.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:05:38 UTC 2021
Edited
by admin
on Sat Jun 26 07:05:38 UTC 2021
Record UNII
BH3B64OKL9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DALFAMPRIDINE
DASH   HSDB   II   MI   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
FAMPRIDINE [INN]
Common Name English
DALFAMPRIDINE [HSDB]
Common Name English
FAMPRIDINE
EMA EPAR   INN   MART.   VANDF   WHO-DD  
INN  
Official Name English
DALFAMPRIDINE [II]
Common Name English
DALFAMPRIDINE [MI]
Common Name English
4-AP
Common Name English
FAMPRIDINE [MART.]
Common Name English
DALFAMPRIDINE [ORANGE BOOK]
Common Name English
AMPYRA
Brand Name English
DALFAMPRIDINE [USAN]
Common Name English
FAMPRIDINE [WHO-DD]
Common Name English
DALFAMPRIDINE [VANDF]
Common Name English
PYRIDIN-4-AMINE
Systematic Name English
DALFAMPRIDINE [USP MONOGRAPH]
Common Name English
FAMPRIDINE (4-AMINOPYRIDINE) [VANDF]
Common Name English
DALFAMPRIDINE [USP-RS]
Common Name English
4-PYRIDINAMINE
Systematic Name English
FAMPRIDINE [VANDF]
Common Name English
FAMPRIDINE [EMA EPAR]
Common Name English
4-AMINOPYRIDINE
Systematic Name English
EL-970
Code English
NSC-15041
Code English
FAMPYRA
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
FDA ORPHAN DRUG 18186
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
FDA ORPHAN DRUG 214205
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
FDA ORPHAN DRUG 104497
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
EMA ASSESSMENT REPORTS FAMPYRA (AUTHORIZED: MULTIPLE SCLEROSIS)
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
EU-Orphan Drug EU/3/07/458
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
NDF-RT N0000192795
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
FDA ORPHAN DRUG 713019
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
LIVERTOX 259
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
WHO-ATC N07XX07
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
WHO-VATC QN07XX07
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
EPA PESTICIDE CODE 69201
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
Code System Code Type Description
INN
7283
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
PUBCHEM
1727
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
MERCK INDEX
M4072
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY Merck Index
HSDB
6037
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
IUPHAR
2416
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
DRUG CENTRAL
4163
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
NCI_THESAURUS
C76777
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
EPA CompTox
504-24-5
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
LACTMED
Dalfampridine
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
CAS
504-24-5
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-987-9
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
USP_CATALOG
1162454
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY USP-RS
MESH
D015761
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
FDA UNII
BH3B64OKL9
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
EVMPD
SUB07505MIG
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
DRUG BANK
DB06637
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
WIKIPEDIA
4-AMINOPYRIDINE
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
ChEMBL
CHEMBL284348
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY
RXCUI
897018
Created by admin on Sat Jun 26 07:05:38 UTC 2021 , Edited by admin on Sat Jun 26 07:05:38 UTC 2021
PRIMARY RxNorm
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
EXCRETED UNCHANGED
URINE
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC